Volcano and ev3 Pair Products for SVG Interventions


April 4, 2007

April 4, 2007 — Volcano Corp. and ev3 Inc. have announced they have entered into a joint marketing and distribution agreement.

Under the terms of the agreement, Volcano will have the opportunity to sell ev3’s SpiderFX Embolic Protection Device in conjunction with its Intravascular Ultrasound (IVUS) and Functional Measurement (FM) devices for use in saphenous vein grafts (SVGs) in the U.S. The SpiderFX is FDA cleared for use during the endovascular treatment of both SVGs and carotid arteries.